Nucleus Laboratories (India) Limted Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 08-12-2024
- Paid Up Capital ₹ 1.00 Cr
as on 08-12-2024
- Company Age 25 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.00 M
as on 08-12-2024
- Revenue -16.11%
(FY 2020)
- Profit -931.97%
(FY 2020)
- Ebitda -878.63%
(FY 2020)
- Net Worth 240.80%
(FY 2020)
- Total Assets 355.29%
(FY 2020)
About Nucleus Laboratories (India) Limted
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹3.00 M.
Ashish Singh, Gyan Shrivastava, Chandana Shrivastava, and One other member serve as directors at the Company.
- CIN/LLPIN
U24231UP1999PLC024944
- Company No.
024944
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
07 Dec 1999
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Nucleus Laboratories (India) Limted?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gyan Shrivastava  | Director | 07-Mar-2022 | Current |
| Ashish Singh | Director | 27-Nov-2000 | Current |
| Chandana Shrivastava | Director | 07-Mar-2022 | Current |
| Debashish Saha | Director | 01-Jun-2023 | Current |
Financial Performance of Nucleus Laboratories (India) Limted.
Nucleus Laboratories (India) Limted, for the financial year ended 2020, experienced significant reduction in revenue, with a 16.11% decrease. The company also saw a substantial fall in profitability, with a 931.97% decrease in profit. The company's net worth Soared by an impressive increase of 240.8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nucleus Laboratories (India) Limted?
In 2020, Nucleus Laboratories (India) Limted had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Global Drugs And Vaccines Private LimitedActive 2 years 9 monthsGyan Shrivastava and Chandana Shrivastava are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 02 Jun 2018 | ₹3.00 M | Open |
How Many Employees Work at Nucleus Laboratories (India) Limted?
Unlock and access historical data on people associated with Nucleus Laboratories (India) Limted, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nucleus Laboratories (India) Limted, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nucleus Laboratories (India) Limted's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
